We are live on
!
Find out more
CS
Credit Suisse Portfolio holdings
AUM
$104B
1-Year Est. Return
34.76%
This Fund
S&P 500
This Quarter
Est. Return
+3.54%
1 Year Est. Return
+34.76%
3 Year Est. Return
+49.35%
5 Year Est. Return
+181.01%
10 Year Est. Return
+395.52%
AUM
$90.3B
AUM Growth
+$7.19B
(+8.7%)
Cap. Flow
+$4.56B
Cap. Flow
% of AUM
5.05%
Top 10 Holdings %
Top 10 Hldgs %
12.91%
Holding
4,527
New
567
Increased
2,145
Reduced
1,207
Closed
344
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$526M |
| 2 |
US Bancorp
USB
|
+$301M |
| 3 |
Pultegroup
PHM
|
+$217M |
| 4 |
BATS
Bats Global Markets, Inc.
BATS
|
+$145M |
| 5 |
Charter Communications
CHTR
|
+$126M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARG
Airgas Inc
ARG
|
+$477M |
| 2 |
Pfizer
PFE
|
+$305M |
| 3 |
iShares China Large-Cap ETF
FXI
|
+$294M |
| 4 |
TWC
TIME WARNER CABLE INC NEW COM STK
TWC
|
+$275M |
| 5 |
XIV
VelocityShares Daily Inverse VIX Short Term ETN
XIV
|
+$255M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 11.61% |
| 2 | Technology | 10.97% |
| 3 | Healthcare | 10.51% |
| 4 | Consumer Discretionary | 7.19% |
| 5 | Industrials | 6.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ATHX
3926
DELISTED
Athersys, Inc. Common Stock
ATHX
| $70K | ﹤0.01% |
1,299
-1,703
| -57% | -$96.5K |
|
3927
Madrigal Pharmaceuticals
MDGL
$12.4B
| $69K | ﹤0.01% |
7,601
+7,007
| +1,180% | +$84.1K |
|
|
GNMX
3928
DELISTED
Aevi Genomic Medicine Inc
GNMX
| $69K | ﹤0.01% |
+12,362
| New | +$64.9K |
|
3929
PhenixFIN
PFX
$83M
| $68K | ﹤0.01% |
+504
| New | +$66.8K |
|
3930
Ameresco
AMRC
$1.04B
| $67K | ﹤0.01% |
+15,410
| New | +$70K |
|
|
NYMX
3931
DELISTED
Nymox Pharmaceutical Corp
NYMX
| $67K | ﹤0.01% |
20,042
-40
| -0.2% | -$98 |
|
|
SDLP
3932
DELISTED
SEADRILL PARTNERS LLC
SDLP
| $67K | ﹤0.01% |
1,239
+41
| +3% | +$2.04K |
|
|
FRBK
3933
DELISTED
Republic First Bancorp Inc
FRBK
| $66K | ﹤0.01% |
15,287
-97,205
| -86% | -$431K |
|
3934
Altimmune
ALT
$581M
| $65K | ﹤0.01% |
+89
| New | +$60.9K |
|
3935
Evolution Petroleum
EPM
$131M
| $65K | ﹤0.01% |
+12,051
| New | +$65K |
|
|
CTLP
3936
DELISTED
Cantaloupe
CTLP
| $64K | ﹤0.01% |
14,959
-31,331
| -68% | -$134K |
|
|
RXII
3937
DELISTED
GALENA BIOPHARMA INC COM
RXII
| $64K | ﹤0.01% |
137,676
+124,163
| +919% | +$57.7K |
|
|
RNWK
3938
DELISTED
RealNetworks Inc
RNWK
| $64K | ﹤0.01% |
+14,794
| New | +$63.9K |
|
|
EGIO
3939
DELISTED
Edgio, Inc. Common Stock
EGIO
| $62K | ﹤0.01% |
+1,048
| New | +$63.5K |
|
3940
Codexis
CDXS
$136M
| $61K | ﹤0.01% |
15,043
-32,729
| -69% | -$120K |
|
3941
Lantheus
LNTH
$6.68B
| $61K | ﹤0.01% |
+16,669
| New | +$38.3K |
|
|
AMRN
3942
Amarin Corp
AMRN
$293M
| $60K | ﹤0.01% |
1,397
-43
| -3% | -$1.62K |
|
3943
Fortress Biotech
FBIO
$113M
| $60K | ﹤0.01% |
+1,491
| New | +$69.4K |
|
3944
Information Services Group
III
$199M
| $60K | ﹤0.01% |
+15,765
| New | +$62.3K |
|
3945
Orion Group Holdings
ORN
$485M
| $60K | ﹤0.01% |
+11,320
| New | +$59.2K |
|
|
CORI
3946
DELISTED
Corium International, Inc.
CORI
| $59K | ﹤0.01% |
+16,990
| New | +$69.2K |
|
3947
Kopin
KOPN
$654M
| $58K | ﹤0.01% |
26,271
+6,216
| +31% | +$12K |
|
3948
Theriva Biologics
TOVX
$9.8M
| $58K | ﹤0.01% |
4
-18
| -82% | -$339K |
|
|
ACGN
3949
DELISTED
Aceragen Inc
ACGN
| $58K | ﹤0.01% |
280
+196
| +233% | +$43.2K |
|
|
CEI
3950
DELISTED
Camber Energy, Inc
CEI
| – | – |
0
| – | – |
|
Similar funds
CSIA
CAN
VAM
CA
MNG
DPAM
ICG
CW
Credit Suisse's Q2 2016 Portfolio in Review
As of Q2 2016, Credit Suisse held 4,527 positions worth $90.3B, up 8.7% from $83.1B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Credit Suisse deployed $4.56B of net new capital in Q2 2016, opening 567 new positions and adding to 2,145 existing holdings. Its largest new stake was Bats Global Markets, Inc.: 5,676,642 shares worth $146M.
By sector, the portfolio is most concentrated in Financials at 12% of assets, down from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Pfizer, an estimated $305M trimmed.
- Credit Suisse's largest Q2 2016 buy was Bats Global Markets, Inc.: 5,676,642 shares worth $146M.
- Credit Suisse added most to State Street SPDR S&P 500 ETF Trust in Q2 2016, an estimated $526M increase.
- Credit Suisse's biggest Q2 2016 reduction was Pfizer, cutting an estimated $305M.
- Credit Suisse fully exited Airgas Inc in Q2 2016, selling an estimated $477M.
- Credit Suisse's ten largest holdings make up 13% of its $90.3B portfolio in Q2 2016.
- Credit Suisse opened 567 new positions and closed 344 in Q2 2016.
- Credit Suisse's portfolio value rose 8.7% quarter-over-quarter to $90.3B.
Based on Credit Suisse's 13F filing for Q2 2016, filed 11 Aug 2016.